DEPLOYDatabase

Company

Smith+Nephew

Smith+Nephew is a British multinational medical technology company headquartered in Watford, England, and a FTSE 100 constituent (LSE: SN, NYSE: SNN).

Track Smith+Nephew
Founded
1856
HQ
Watford, England, UK
Status
public (LSE: SN; NYSE: SNN)

Models

1

Overview

Smith+Nephew is a British multinational medical technology company headquartered in Watford, England, and a FTSE 100 constituent (LSE: SN, NYSE: SNN). Founded in 1856 by Thomas James Smith in Kingston upon Hull, the company develops the CORI handheld robotic surgical platform for orthopaedic procedures including partial and total knee arthroplasty and shoulder arthroplasty. Smith+Nephew reported $6.16B revenue in 2025 and employs approximately 18,000 people across 100+ countries.

Verified record

Verified deployments
None on file
Active incidents
None on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

Product

CORI Surgical System (handheld, imageless robotic knee surgery); NAVIO successor.

Boundary

AI-augmented surgeon-controlled handheld assistance, NOT autonomous.

Stock listings

LSE: SN; NYSE: SNN

Acquisition

Acquired Blue Belt Technologies (NAVIO) in 2015 for $275M

CEO

Deepak Nath (appointed April 2022)

Chairman

Rupert Soames

Revenue

US$6.164B (2025)

Operating income

US$794M (2025)

Employees

18,000 (2025)

Listed

LSE: SN, NYSE: SNN

Founder

Thomas James Smith (1856)

Data & sources

Web sources

3

3 sources backing this record.View all →

Models (1)

View all models →

Current platform

CORI

The CORI Surgical System is Smith+Nephew's compact, surgeon-controlled handheld robotics platform for orthopedic knee surgery, recorded in the surgical form factor as the handheld, imageless, smaller-footprint archetype of the orthopedic sub-cohort. Unlike Stryker's Mako, which uses a pre-operative CT scan and a large robotic arm, CORI is imageless: the surgeon paints the joint surface intra-operatively to build a three-dimensional bone model, then uses a handheld robotic bur whose cutting speed and exposure are robotically controlled to the surgical plan, with optical navigation via a passive infrared camera that Smith+Nephew states is four times faster with twice the cutting volume of the prior NAVIO system. Because the surgeon physically holds and moves the tool throughout while the software does the imageless mapping, planning, and intra-operative tracking that governs the bur, CORI is AI-augmented surgeon-controlled assistance and not autonomous, and it is in scope as a surgical robot. Made by Smith+Nephew, listed as SN in London and SNN in New York, the system descends from Smith+Nephew's October 2015 acquisition of Blue Belt Technologies for 275 million dollars, whose NAVIO handheld system evolved into CORI at its July 14, 2020 launch alongside the Real Intelligence platform. Its robotic-cutting scope is cleared for total, partial or unicompartmental, and revision knee, with revision knee a 2022 first-to-market indication on a robotics platform; its hip capability is navigation only, through RI.HIP NAVIGATION cleared in January 2022, and is not robotic burring, a distinction several secondary sources blur. The platform is positioned for ambulatory surgery centers and outpatient operating rooms, and no CORI-specific installed-base or procedure-volume figure is asserted here because none was verified against Smith+Nephew investor disclosure.

surgicalView model →

Smith+Nephew on the deployment map

Where Smith+Nephew's robots are verified operating. Explore the deployment map by place and type.

Explainers

Plain-language answers to the questions people ask about Smith+Nephew, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is Smith+Nephew CORI?

    Smith+Nephew CORI is a handheld imageless orthopedic surgical robotic system from Smith+Nephew (LSE: SN / NYSE: SNN). Per Agent A orthopedic ingest: FDA-cleared for total + partial + revision knee. CRITICAL HONESTY DISTINCTION: hip is NAVIGATION-ONLY, NOT robotic; common aggregator confusion blurs this; surfaced explicitly with cap-flag (knee is robotic; hip is navigation-only). Acquired Blue Belt Technologies 2015 → Navio → CORI 2020 evolution lineage. AI-augmented surgeon-controlled assistance (NOT autonomous; same assistive class as Mako + da Vinci + ROSA). Editorial throughline: handheld imageless commercial-niche archetype distinct from Stryker Mako's large-footprint CT-based architecture; knee-only robotic scope with navigation-only hip; smaller-footprint OR integration. Cohort positioning: handheld imageless orthopedic archetype within the surgical cluster's Wave 3 orthopedic sub-cohort triangle.

Current leadership (4)

Board (2)

Safety record

No incidents on record for Smith+Nephew.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Smith+Nephew in third-party press

Smith+Nephew announces first clinical cases with the next generation CORI XT Handheld Robotics Platform across knee and shoulder arthroplasty

Jun 8, 2026

Smith+Nephew Announces New Strategy and 2028 Financial Targets

Dec 8, 2025

Smith+Nephew to showcase its CORI Surgical System at surgical clinics across Germany Austria and Switzerland

May 5, 2025

Peer companies